A phase II, multicentre study of oral LBH589 [panobinostat] in patients with chronic phase chronic myeloid leukemia with resistant disease following treatment with at least two BCR-ABL tyrosine kinase inhibitors.

Trial Profile

A phase II, multicentre study of oral LBH589 [panobinostat] in patients with chronic phase chronic myeloid leukemia with resistant disease following treatment with at least two BCR-ABL tyrosine kinase inhibitors.

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Apr 2015

At a glance

  • Drugs Panobinostat (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 22 Jun 2012 Planned number of patients changed from 120 to 130 and additional locations added as reported by European Clinical Trials Database record.
    • 24 Apr 2012 Actual end date changed from May 2008 to Sep 2008 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top